Abstract:Pharmacological chaperones (PC's) are an emerging class of cell permeant small molecules that can stabilise the folding of misfolded variant proteins, thus restoring function. G protein‐coupled receptors (GPCRs) are a family of plasma membrane associated receptors that have been shown to be amenable to PC rescue. The review provides a comprehensive analysis of the current research landscape of pharmacological chaperone (PC) 'rescue' of GPCRs, with a particular focus on rescuing inactivating variant GPCRs that play essential roles in the hypothalamic‐pituitary gonadal axis. G protein‐coupled receptors (GPCRs) are central to the functioning of the hypothalamic–pituitary–gonadal axis (HPG axis) and include the rhodopsin‐like GPCR family members, neurokinin 3 receptor, kappa‐opioid receptor, kisspeptin 1 receptor, gonadotropin‐releasing hormone receptor, and the gonadotropin receptors, luteinizing hormone/choriogonadotropin receptor and follicle‐stimulating hormone receptor. Unsurprisingly, inactivating variants of these receptors have been implicated in a spectrum of reproductive phenotypes, including failure to undergo puberty, and infertility. Clinical induction of puberty in patients harbouring such variants is possible, but restoration of fertility is not always a realisable outcome, particularly for those patients suffering from primary hypogonadism. Thus, novel pharmaceuticals and/or a fundamental change in approach to treating these patients are required. The increasing wealth of data describing the effects of coding‐region genetic variants on GPCR function has highlighted that the majority appear to be dysfunctional as a result of misfolding of the encoded receptor protein, which, in turn, results in impaired receptor trafficking through the secretory pathway to the cell surface. As such, these intracellularly retained receptors may be amenable to 'rescue' using a pharmacological chaperone (PC)‐based approach. PCs are small, cell permeant molecules hypothesised to interact with misfolded intracellularly retained proteins, stabilising their folding and promoting their trafficking through the secretory pathway. In support of the use of this approach as a viable therapeutic option, it has been observed that many rescued variant GPCRs retain at least a degree of functionality when 'rescued' to the cell surface. In this review, we examine the GPCR PC research landscape, focussing on the rescue of inactivating variant GPCRs with important roles in the HPG axis, and describe what is known regarding the mechanisms by which PCs restore trafficking and function. We also discuss some of the merits and obstacles associated with taking this approach forward into a clinical setting.

Functional Rescue of Kallmann Syndrome-associated Prokineticin Receptor 2 (PKR2) Mutants Deficient in Trafficking

Disease-causing Mutation in PKR2 Receptor Reveals a Critical Role of Positive Charges in the Second Intracellular Loop for G-protein Coupling and Receptor Trafficking

[Clinical Features and PRRT2 Gene Mutation in Paroxysmal Kinesigenic Dyskinesia].

Novel mutation of the PRRT2 gene in two cases of paroxysmal kinesigenic dyskinesia: Two case reports

Functional Analysis of the Distal Region of the Third Intracellular Loop of PROKR2.

Restoring function to inactivating G protein‐coupled receptor variants in the hypothalamic–pituitary–gonadal axis

A functional spectrum of PROKR2 mutations identified in isolated hypogonadotropic hypogonadism

PROKR2 Mutations in Idiopathic Hypogonadotropic Hypogonadism: Selective Disruption of the Binding to a Gα‐protein Leads to Biased Signaling

Genetic Polymorphisms of Prokineticins and Prokineticin Receptors Associated with Human Disease

Role of N-Linked Glycosylation in PKR2 Trafficking and Signaling

Enhanced phosphorylation-independent arrestins and gene therapy.

Clinical Manifestations in Paroxysmal Kinesigenic Dyskinesia Patients with Proline-Rich Transmembrane Protein 2 Gene Mutation

Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells

Genetic and phenotypic analyses of PRRT2 positive and negative paroxysmal kinesigenic dyskinesia

Enhanced Arrestin Facilitates Recovery and Protects Rods Lacking Rhodopsin Phosphorylation

Mutation Analysis of MR-1, SLC2A1, and CLCN1 in 28 PRRT2-negative Paroxysmal Kinesigenic Dyskinesia Patients.

Loss-of-function Mutation in the Prokineticin 2 Gene Causes Kallmann Syndrome and Normosmic Idiopathic Hypogonadotropic Hypogonadism

The Novel Function of Mir‐3195 for Mutant PROK2 (c.223‐4c>a) Degradation

Aberrant Transcriptional Networks in Step-Wise Neurogenesis of Paroxysmal Kinesigenic Dyskinesia-Induced Pluripotent Stem Cells.

Prokineticins and their G protein-coupled receptors in health and disease.

PRRT2 Truncated Mutations Lead to Nonsense-Mediated Mrna Decay in Paroxysmal Kinesigenic Dyskinesia